Skip to content

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

Paris, France, February 21, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that enrollment in REVERSE, a Phase III clinical trial of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy (LHON), has been successfully completed.

Please find the full PDF press release attached.

 

Contacts

GenSight Biologics
Thomas Gidoin
Chief Financial Officer
ir@gensight-biologics.com
+33 (0)1 76 21 72 20
NewCap
I
nvestor Relations
Florent Alba
gensight@newcap.eu
+33 (0)1 44 71 98 55
Rooney Partners
Media Relations
Marion Janic
mjanic@rooneyco.com
+1-212-223-4017

 


Source: Gensight